[EN] INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS<br/>[FR] COMPOSÉS D'INDOLE ET D'INDAZOLE EN TANT QU'INHIBITEURS DE NÉCROSE CELLULAIRE
申请人:LG LIFE SCIENCES LTD
公开号:WO2009025478A1
公开(公告)日:2009-02-26
The present invention relates to indole or indazole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole or indazole compounds as an active ingredient.
2-Substituted indoles have been efficiently obtained by selective arynic cyclisation of halogenated aryl imines of methyl ketones in the presence of the complex-base NaNH2–ButONa and by PhCH2SH–AlCl3 opening of tetrahydrothiopyranoindoles also obtained from arynic cyclisation of imines.
Palladium-catalyzed oxidation of amino alkenes to cyclic imines or enamines and amino ketones
作者:B. Pugin、L. M. Venanzi
DOI:10.1021/ja00361a023
日期:1983.11
n NH 2 (n=3,4) se cyclisent en pyrrolines-1 ou tetrahydro-3,4,5,6 pyridines dans les conditions du procede Wacker. Les aminoalcenes avec un groupe amino secondaire donnent les imines cycliques correspondantes, tandis que les alcenes avec un groupe amino tertiaire donnent des aminocetones
Lesaminoalcenes du type CH 2 =CH(CH 2 ) n NH 2 (n=3,4) se cyclisent en pyrrolines-1 ou tetrahydro-3,4,5,6 pyridines dans les conditions du procede Wacker。Lesaminoalcenes avec un groupe amino secondaire donnent les imines cycliquesrespondantes, tandis que les alcenes avec un groupeamino tertiaire donnent desaminocetones
HISTONE MODIFICATION INHIBITOR SPECIFIC TO TARGET GENE
申请人:Nagase Hiroki
公开号:US20110160399A1
公开(公告)日:2011-06-30
The present invention provides a target gene-specific histone modification regulator, which comprises a conjugate between a histone modification regulator and a polyamide capable of recognizing a regulatory region in a target gene. This enables the provision of a target gene-specific histone modification regulator.
Antibacterial compounds of formula I are provided:
As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.